Shi Shu-Zhen, Liu Ming, Gao Ya, Xu Jian-Guo, Kang Ying-Ying, Xing Li-Na, Zhou Zheng, Tian Jin-Hui
Evidence-based Medicine Center, Lanzhou University Lanzhou 730000, China School of Basic Medical Sciences, Lanzhou University Lanzhou 730000, China.
School of Basic Medical Sciences, Lanzhou University Lanzhou 730000, China.
Zhongguo Zhong Yao Za Zhi. 2021 Aug;46(15):3998-4007. doi: 10.19540/j.cnki.cjcmm.20210113.501.
To summarize and evaluate the efficacy and safety of Shenmai Injection in the treatment of viral myocarditis, shock, pulmonary heart disease, coronary heart disease, neutropenia and tumor chemotherapy, so as to provide supportive evidences for clinical rational use of Shenmai Injection. By searching literatures about studies on the systematic reviews on Shenmai Injection in treatment of viral myocarditis, shock, pulmonary heart disease, coronary heart disease, neutropenia and tumor chemotherapy from the main Chinese and English databases. Primary efficacy and safety outcome measures were selected for comparative analysis and summary, and the appraisal tool of AMSTAR 2 was used to evaluate the included studies.A total of 36 systematic reviews(published from 2005 to 2020) were included, involving viral myocarditis, shock, pulmonary heart disease, malignant tumor and coronary heart disease. The number of cases included in each type of the above diseases was 3 840, 2 484, 12 702, 28 036 and 27 082, respectively. The comparison results showed that, Shenmai Injection combined with conventional/western medicine treatment groups had better efficacy than conventional/western medicine groups alone in the prevention and treatment of the above five diseases. The main adverse reactions of Shenmai Injection reported in the included studies were facial flushing, rash, palpitation, etc., but the incidence was low and the general symptoms were mild, so no special treatment was needed. Therefore, the application of Shenmai Injection on the basis of conventional treatment or western medicine treatment had better prevention and treatment efficacy of the diseases. It was suggested that more multi-center and larger sample-size randomized controlled trials should be carried out in the future, and the relevant reporting standards should be strictly followed in systematic reviews, so as to improve the scientificity and transparency of the study.
总结和评价参麦注射液治疗病毒性心肌炎、休克、肺心病、冠心病、中性粒细胞减少症及肿瘤化疗的疗效和安全性，为临床合理使用参麦注射液提供支持依据。通过检索中文和英文主要数据库中关于参麦注射液治疗病毒性心肌炎、休克、肺心病、冠心病、中性粒细胞减少症及肿瘤化疗的系统评价研究文献。选择主要疗效和安全性结局指标进行对比分析和总结，并采用AMSTAR 2评价工具对纳入研究进行评价。共纳入36篇系统评价（发表时间为2005年至2020年），涉及病毒性心肌炎、休克、肺心病、恶性肿瘤和冠心病。上述每种疾病纳入的病例数分别为3840例、2484例、12702例、28036例和27082例。对比结果显示，参麦注射液联合常规/西药治疗组在防治上述5种疾病方面的疗效优于单纯常规/西药组。纳入研究中报道的参麦注射液主要不良反应为面部潮红、皮疹、心悸等，但发生率低且一般症状较轻，无需特殊处理。因此，在常规治疗或西药治疗基础上加用参麦注射液对疾病具有较好的防治效果。建议未来开展更多多中心、大样本量的随机对照试验，并在系统评价中严格遵循相关报告标准，以提高研究的科学性和透明度。
